Lets hope the quarterly tomorrow doesn't contain any surprises...

Lets hope the quarterly tomorrow doesn't contain any surprises or ambiguous comments.

It would be pretty damn nice to read 'The FDA have expressed complete satisfaction with all outstanding issues. We are delighted to announce the FDA have classified this BLA as an express review which will take 6 weeks'

That would see the SP at $3+ within 2 or 3 weeks I'd wager, if not higher.

There's just too much money flowing into buying MSB shares, and add that to the company / board on-market purchases - plus the fact the FDA reached out to MSB - then the market seems confident that the FDA are happy with all that MSB have done to address concerns.

The only thing that causes pause is that damn phrase "seeking to address all remaining product characterization issues".

I'd really like to get absolute clarity on what those remaining issues are.